second generation 4-1BBζ B7H3-EGFRt-DHFR

Second generation 4-1BBζ B7H3-EGFRt-DHFR is an autologous cell therapy product consisting of CD4+ and CD8+ T cells that have been genetically modified using a lentiviral vector to express a chimeric antigen receptor (CAR) targeting the immune checkpoint protein B7-H3 (CD276). The CAR construct incorporates a costimulatory domain from 4-1BB (CD137) and a CD3-zeta signaling domain, which together enhance T cell activation and persistence. The engineered T cells also express EGFRt, which serves as both a tracking marker and an inducible safety switch for targeted elimination of the CAR-T cells in case of severe toxicity. Additionally, DHFR is included as part of the selection or safety system. This therapy is being developed primarily for pediatric and young adult patients with relapsed or refractory non-central nervous system solid tumors that overexpress B7-H3[5][4].

Other names

B7H3 CAR T Cell ImmunotherapyB-7H3 CAR T Cell ImmunotherapyB 7H3 CAR T Cell ImmunotherapyB7-H3-specific CAR T cellsB-7-H3-specific CAR T cellsB 7-H3-specific CAR T cellsSCRI-CARB7H3(s)x19